Emergent BioSolutions Secures $150M Loan, Extends Maturities to 2031 and Cuts Interest 200bps
Emergent BioSolutions will report first-quarter 2026 financial results on April 30 via webcast and telephone conference call. The company closed a new $150 million term loan and amended its $50 million asset-based loan, extending both maturities to April 2031 and reducing term loan interest by 200 basis points.
1. First-Quarter 2026 Results Conference Call
Emergent BioSolutions will host its first-quarter 2026 financial results teleconference on April 30 at 5:00 p.m. Eastern. Investors can join live via webcast on the company’s website or by telephone after advance registration for dial-in details and passcode.
2. Loan Refinancing and Asset-Based Loan Amendment
The company closed a $150 million term loan with OrbiMed and repaid its prior facility, while amending its Wells Fargo asset-based loan to $50 million. Both facilities now mature on April 16, 2031, and the term loan’s interest rate has been cut by 200 basis points, enhancing financial flexibility.